Health knowledge made personal
Join this community!
› Share page:
Go
Search posts:

Interferon Alpha Hybrids

Posted Jul 31 2007 5:00pm

Description of Invention:
Available for licensing are hybrid interferon alpha (INF-alpha) polypeptides constructed by combinations of INFalpha21b and INFalpha2c, and mutants of these hybrids. These hybrid constructs have resulted in novel IFNs that either combine different biological properties from the parent proteins or have significantly different biological activity from both the parents in anti-proliferative, anti-viral, or competitive binding properties. For instance, the hybrid designated HY-3 has higher anti-proliferative activity in Daudi, WISH, and primary human lymphocyte cells exhibiting approximately 6 times higher anti-proliferative activity than either parent IFN. These IFN hybrids provide a powerful tool for studying the structure-function relationship of these molecules. The engineered IFN-alpha proteins may have important new therapeutic applications and may provide greater insights into understanding of the clinical activities of existing IFN-alphas.

Also available for licensing are hybrid INF-alpha nucleic acids encoding the hybrid polypeptides as well as cells, vectors, pharmaceutical compositions with these nucleic acid sequences.

Applications:
  • Anti-viral and cancer therapeutics.
  • Research tool to study IFN-alpha functions.


Development Status:
The technology is currently in the pre-clinical stage of development.

Inventors:
Kathryn C Zoon (FDA)


Patent Status:
HHS, Reference No. E-068-1998/0
US, , Patent No. 6,685,933, Issued 03 Feb 2004
US, , Patent No. 7,235,232, Issued 26 Jun 2007
PCT, Application No. PCT/US99/15284 filed 06 Jul 1999


Relevant Publication:
  1. R Hu et al. Protein engineering of interferon alphas. Methods Mol Med. 2005;116:69-80. [ PubMed abs ]
  2. R Hu et al. Human IFN-alpha protein engineering: the amino acid residues at positions 86 and 90 are important for antiproliferative activity. J Immunol. 2001 Aug 1;167(3):1482-1489. [ PubMed abs ]
  3. R Hu et al. Divergence of binding, signaling, and biological responses to recombinant human hybrid IFN. J Immunol. 1999 Jul 15;163(2):854-860. [ PubMed abs ]


Licensing Status:
Available for licensing.


Portfolios:
Devices/Instrumentation
Devices/Instrumentation - Research Tools and Materials
Cancer
Cancer - Therapeutics
Cancer - Research Materials
Infectious Diseases
Infectious Diseases - Therapeutics
Infectious Diseases - Research Materials
Internal Medicine
Internal Medicine - Therapeutics
Internal Medicine - Research Materials



For Additional Information Please Contact:
Jennifer Wong
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Email: wongje@mail.nih.gov
Phone: 301-435-4633
Fax: 301-402-0220


Ref No: 1613

Updated: 08/2007

Post a comment
Write a comment:

Related Searches